Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma
Executive Summary
The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.
You may also be interested in...
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Scrip Asks… What Does 2019 Hold For Biopharma? Part 2: Business Trends
What do biopharma leaders and experts expect for the coming year? Following on from therapeutic area insights in part 1, our interviewees consider the outlook for business trends, from M&A and financing to digital strategy, AI and organizational management.
Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack
Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.